MAT1A and metabolic dysfunction-associated steatotic liver disease: Of note is the observation that SAMe treatment of Mat1a-KO mice reverses liver damage and the finding that, in NAFLD patients, the expression of major enzymes involved in 1CM, including MAT1A, is impaired, and the concentration of SAMe in the liver reduced.